Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics in Preterm Infants
NCT07296718Phase 4Completed
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 4 trial of Lactobacillus rhamnosus GG, bifidobacterium BB-12 + lactobacillus paracasei + lactobacillus casei-431 + streptococcus thermophilus TH-4 in necrotizing enterocolitis (NEC), sepsis, feeding intolerance. Started May 2023; status: completed.
02
Drugs
Lactobacillus rhamnosus GGbifidobacterium BB-12 + lactobacillus paracasei + lactobacillus casei-431 + streptococcus thermophilus TH-4
03
Conditions
necrotizing enterocolitis (NEC)sepsisfeeding intolerance
Beyond the preview
Go deeper on NCT07296718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296718.